Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $18.44 Analyst target: $27.50 Upside: 49.13%
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
See the full interactive analysis & chart →Informational only — not investment advice.